Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump
Will Medtronic follow Walgreen and abandon inversion in Covidien deal?
August 15, 2014 by Brad Perriello
ConMed Corp., Coppersmith Capital Management, Covidien, electroCore, Medtronic, Pershing Square Capital Management, Piper Jaffray, Valeant Pharmaceuticals, Voce Capital Management, Allergan Inc.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1neBVhX
Cap comentari:
Publica un comentari a l'entrada